We have reached our next milestone of 85,000 followers on LinkedIn! Thank you to all our clients, candidates and wider network who have followed our journey since 2019. We look forward to continuing to connect with you all, providing industry insights and news as well as incredible opportunities within the Pharmaceutical and Life Science space. #followers #milestone #recruitment
Mantell Associates
Executive Search Services
City of London, England 85,352 followers
Multidiscipline Global Life Science and Pharmaceutical Headhunting Firm.
Über uns
Mantell Associates is a multi-discipline headhunting firm focused on providing both permanent and contract recruitment services globally, to the Biotech, Pharmaceutical, CDMO, CRO, Diagnostics, Animal Health, Consulting, Medical Device and MedTech sectors. With success ranging across C-Suite, Commercial, Technical Operations, Scientific, Clinical, Quality and Regulatory, we pride ourselves on our ability to bring the top talent to our clients, and the best opportunities to the top talent. Our services span across our Partnership Service, Contingency, Project Management and Contract models, meaning that we can cater to our client’s every requirement.
- Website
-
www.mantellassociates.com
External link for Mantell Associates
- Industrie
- Executive Search Services
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- City of London, England
- Typ
- In Privatbesitz
- Gegründet
- 2019
- Spezialitäten
- Contract Development Manufacturing Organisations, Contract Manufacturing Organisations, Preclinical, Active Pharmaceutical Ingredients, Cell & Gene Therapy, Finished Dosage Forms, Biologics, Toxicology, Pharmacology, Oncology, CDMO, CMO, Biomarkers, Vaccines, Contract Research Organisation, Clinical Trial Supplies, Bioanalytics, Bioanalysis, Fine Chemicals, and Highly Potent Active Pharmaceutical Ingredients
Standorte
-
Primäre
150 Minories
City of London, England EC3N 1LS, GB
-
2 S Biscayne Blvd
Miami, Florida 33131, US
-
Rigistrasse 3
Zug, 6300, CH
Employees at Mantell Associates
Aktualisierungen
-
Visiox Pharmaceuticals Inc. has entered into a definitive merger agreement with Ocuvex Therapeutics Inc., a privately held ophthalmic pharmaceutical company that boasts a robust pipeline of near-term ophthalmic medicines. Together they aim to emerge as a leader in the eye care sector with a strong portfolio of ophthalmic medicines. Read more: https://lnkd.in/edw4XXCH #ophthalmic #eyecare #ophthalmicmedicines
-
A huge thank you to Tom Bryan as he celebrates one year at Mantell Associates! Tom joined the MA team in August 2023 to set up and lead our UK Contract division. Over the past year he has built out our contract book, signed a record number of new clients across the US and Europe, expanded his team, and has been a great addition to the London office! Congratulations on your one year anniversary Tom! #workanniversary #team #thankyou
-
-
ST PHARM, a technology-driven RNA CDMO, and Quantoom Biosciences, a specialised RNA technology platform developer, have teamed up to accelerate the development and manufacturing of RNA-based vaccines and therapeutics. Read more: https://lnkd.in/eyncw3Qb #RNA #vaccines #CDMO
ST Pharm, Quantoom Partner to Accelerate RNA Vaccine and Therapeutic Development
contractpharma.com
-
FUJIFILM Diosynth Biotechnologies, a contract development and manufacturing organisation (CDMO), has opened a microbial fermentation manufacturing facility in Billingham, which triples microbial production throughput. Read more: https://lnkd.in/e86fsx8c #microbialfermentation #CDMO #microbialproduction
Fujifilm Diosynth Opens Billingham, UK Microbial Manufacturing Facility
contractpharma.com
-
Thomas White discusses the dominance of CRDMOs compared to CDMOs. This article explores the rise of CRDMOs, their advantages over traditional CDMOs, and the strategic value of incorporating research and development (R&D) into the outsourcing model. Read more: https://lnkd.in/eEKB77bp #researchanddevelopment #CRDMO #research
The Dominance of CRDMOs Compared to CDMOs
https://www.mantellassociates.com
-
Our CEO Alessandro Mantell leading from the front! A great testimonial from one of our longest-standing partners in the CDMO space. "Top notch service provided by Alessandro and Mantell Associates. I have worked with them to rapidly build multiple commercial organizations." #testimonialtuesday #clienttestimonial #recommendation
-
-
Bridge Biotherapeutics, Inc., a clinical-stage biotechnology company, has formed a strategic alliance with HitGen Inc., a leading Chinese drug discovery platform company, to accelerate the development of novel anticancer drug candidates. The collaboration builds upon the success of initial hit finding and identification work utilising HitGen Inc.'s DNA-encoded library (DEL) technology. Read more: https://lnkd.in/esAZgCVF #drugdiscovery #anticancer #cancertherapeutics
Bridge Biotherapeutics and HitGen Team Up for Oncology Drug Discovery
contractpharma.com
-
eXmoor Pharma, a provider of cell and gene therapy manufacturing services, has achieved a significant milestone with the receipt of a Manufacturing and Import Authorization for Investigational Medicinal Products (MIA(IMP)) license from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This authorization allows eXmoor to manufacture good manufacturing practice (GMP)-grade cell and gene therapy materials for use in clinical trials. Read more: https://lnkd.in/ec-aqu8x #celltherapy #RNAResearch #FDAApproval #PharmaCompliance
eXmoor Pharma Receives MIA(IMP) License for Cell & Gene Therapy
contractpharma.com
-
Novartis has announced the formation of Borealis Biosciences, Inc., an independent, discovery-stage biotechnology company focused on developing next-generation xRNA-based medicines for kidney diseases. The new company is a result of a partnership between Novartis and Versant Ventures, and is based in Vancouver, Canada. Read more: https://lnkd.in/eF7ADYyw #kidneydisease #advancedtherapies #xRNA
Novartis and Versant Partner to Form Kidney Disease Biotech
contractpharma.com